Overview

A Study to Assess the Efficacy, Safety and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
0
Participant gender:
All
Summary
Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study. The diseases characterized by chronic pruritus investigated in this pilot study currently include chronic idiopathic urticaria (CIU), chronic idiopathic pruritus (CIP), lichen planus (LP), lichen simplex chronicus (LSC) and plaque psoriasis (PPs).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kiniksa Pharmaceuticals, Ltd.
Criteria
Inclusion Criteria:

1. Male or female aged 18 to 75 years

2. Have clinical diagnosis of CIU, CIP, LP, LSC and PPs for at least 6 months

3. Moderate to severe pruritus

4. Female participants of childbearing potential must have a negative pregnancy test, be
nonlactating, and having agreed to use a highly effective method of contraception, as
specified in the protocol, from the Screening Visit until 10 weeks after final study
drug administration

5. Able to comprehend and willing to sign an Informed Consent Form and able to abide by
the study restrictions and comply with all study procedures for the duration of the
study

Exclusion Criteria:

1. Use of prohibited medications within the indicated timeframe from Day 1 to the End of
Study

2. Is currently using medication known to cause pruritus

3. Has any inflammatory, pruritic, and/or fibrotic skin condition other than the
diagnosis that defines inclusion

4. Laboratory abnormalities that fall outside the windows specified in the protocol at
the Screening Visit

5. Has an active infection, including skin infection

6. Any medical or psychiatric condition which, in the opinion of the Investigator or the
Sponsor, may place the participant at increased risk as a result of study
participation, interfere with study participation or study assessments, affect
compliance with study requirements, or complicate interpretation of study results